Astria Therapeutics to present at upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting

Astra Therapeutics announced that it will present interim quality of life results from the ALPHA-STAR trial of navenibart (STAR-0215) at the Canadian Society of Allergy and Clinical Immunology (CSACI) Annual Scientific Meeting in Banff, Canada on 7 November 2024.

Adil Adatia MD, Assistant Professor in the Department of Medicine at the University of Alberta in Edmonton, Alberta and Director of the University of Alberta Angioedema Centre of Reference and Excellence (ACARE), will present a poster titled: Quality of life (QoL) improvements in hereditary angioedema (HAE) with STAR-0215; interim results from the phase 1b/2 ALPHA-STAR clinical trial. The poster will be exhibited in the Van Horne Foyer from 10:00am Mountain Daylight Time on Thursday 7 November until the end of day on Saturday 9 November 2024.

(Source: Astria)